{"id":58761,"date":"2026-03-04T16:42:58","date_gmt":"2026-03-04T08:42:58","guid":{"rendered":"https:\/\/flcube.com\/?p=58761"},"modified":"2026-03-04T16:42:59","modified_gmt":"2026-03-04T08:42:59","slug":"sihuan-pharmas-bireociclib-wins-nmpa-approval-for-first-line-hr-her2-breast-cancer-cdk2-4-6-inhibitor-expands-label","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58761","title":{"rendered":"Sihuan Pharma&#8217;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label"},"content":{"rendered":"\n<p><strong>Sihuan Pharmaceutical Holdings Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/0460:HKG\">HKG:\u202f0460<\/a>)<\/strong> announced that <strong>Xuanyuening (bireociclib)<\/strong>, a <strong>Category\u202f1 CDK2\/4\/6 inhibitor<\/strong> developed by subsidiary <strong>Xuanzhu Biopharmaceutical<\/strong>, has received <strong>NMPA approval<\/strong> for <strong>first\u2011line treatment<\/strong> of <strong>HR+\/HER2\u2011 advanced breast cancer<\/strong> in <strong>combination with an aromatase inhibitor (AI)<\/strong>. The approval\u2014based on <strong>BRIGHT\u20113 study data<\/strong> showing <strong>superior progression\u2011free survival<\/strong>\u2014marks the <strong>third indication<\/strong> for the <strong>first\u2011in\u2011class multi\u2011target CDK inhibitor<\/strong> in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460)<\/td><\/tr><tr><td><strong>Subsidiary<\/strong><\/td><td>Xuanzhu Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Xuanyuening (bireociclib)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td><strong>First CDK2\/4\/6 inhibitor approved in China<\/strong><\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>First\u2011line HR+\/HER2\u2011 advanced breast cancer + aromatase inhibitor<\/td><\/tr><tr><td><strong>Prior Approvals (May\u202f2025)<\/strong><\/td><td>\u2460 + fulvestrant (post\u2011endocrine therapy); \u2461 Monotherapy (heavily pretreated)<\/td><\/tr><tr><td><strong>Clinical Study<\/strong><\/td><td>BRIGHT\u20113 (NCT05257395)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bright-3-efficacy-data\">BRIGHT\u20113 Efficacy Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Bireociclib + AI<\/th><th>Control (AI alone)<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Median PFS (Investigator)<\/strong><\/td><td><strong>Not reached<\/strong><\/td><td>18.43 months<\/td><td>Superior durability<\/td><\/tr><tr><td><strong>Median PFS (IRC)<\/strong><\/td><td><strong>Not reached<\/strong><\/td><td>19.55 months<\/td><td>Consistent benefit<\/td><\/tr><tr><td><strong>Interpretation<\/strong><\/td><td>Greater proportion progression\u2011free<\/td><td>\u2014<\/td><td><strong>Durable efficacy advantage<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-cdk2-4-6-inhibition\">Mechanism of Action \u2013 CDK2\/4\/6 Inhibition<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Function<\/th><th>Therapeutic Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>CDK4\/6<\/strong><\/td><td>Cell cycle regulation<\/td><td>Established efficacy in HR+ breast cancer<\/td><\/tr><tr><td><strong>CDK2<\/strong><\/td><td>Cell cycle progression + resistance mechanism<\/td><td><strong>Unique multi\u2011target synergy<\/strong>; addresses CDK4\/6 inhibitor resistance<\/td><\/tr><tr><td><strong>Combined Effect<\/strong><\/td><td>Triple CDK blockade<\/td><td><strong>Potent tumor suppression<\/strong> + <strong>reduced hematologic toxicity<\/strong> vs. CDK4\/6\u2011only inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Line Market Expansion:<\/strong> The <strong>AI combination approval<\/strong> positions bireociclib for <strong>front\u2011line use<\/strong>\u2014the <strong>largest HR+\/HER2\u2011 breast cancer segment<\/strong> (~\u202f70% of metastatic cases)\u2014vs. prior <strong>restricted to post\u2011endocrine or heavily pretreated settings<\/strong>.<\/li>\n\n\n\n<li><strong>CDK2 Differentiation:<\/strong> As the <strong>only CDK2\/4\/6 inhibitor<\/strong>, bireociclib offers <strong>mechanistic differentiation<\/strong> from <strong>palbociclib, ribociclib, abemaciclib<\/strong> (CDK4\/6\u2011only), potentially <strong>overcoming resistance<\/strong> and <strong>improving safety<\/strong> (reduced neutropenia).<\/li>\n\n\n\n<li><strong>Monotherapy Leadership:<\/strong> The <strong>May\u202f2025 monotherapy approval<\/strong>\u2014<strong>first and only in China<\/strong>\u2014establishes <strong>unique positioning<\/strong> for <strong>chemotherapy\u2011ineligible or endocrine\u2011resistant patients<\/strong> unable to tolerate combination therapy.<\/li>\n\n\n\n<li><strong>Sihuan Innovation Pivot:<\/strong> <strong>Three indications within 10 months<\/strong> demonstrates <strong>Xuanzhu&#8217;s oncology capabilities<\/strong>, supporting <strong>Sihuan&#8217;s transformation<\/strong> from <strong>traditional pharma<\/strong> to <strong>innovation\u2011driven biopharma<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>China HR+\/HER2\u2011 Breast Cancer Market<\/strong><\/td><td>~\u202f$2\u202fbillion; CDK4\/6 inhibitors standard of care; bireociclib&#8217;s CDK2 component offers resistance solution<\/td><\/tr><tr><td><strong>CDK4\/6 Inhibitor Competition<\/strong><\/td><td>Palbociclib (Pfizer), ribociclib (Novartis), abemaciclib (Eli Lilly) dominate; bireociclib&#8217;s multi\u2011target profile and reduced toxicity differentiate<\/td><\/tr><tr><td><strong>First\u2011Line Treatment Share<\/strong><\/td><td>Front\u2011line positioning captures <strong>largest patient volume<\/strong> and <strong>longer treatment duration<\/strong> vs. later\u2011line settings<\/td><\/tr><tr><td><strong>Global Potential<\/strong><\/td><td>China\u2011first approval supports <strong>US\/EU partnership<\/strong> or <strong>out\u2011licensing<\/strong> for global CDK2\/4\/6 market entry<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding first\u2011line market penetration, competitive positioning vs. CDK4\/6\u2011only inhibitors, and global expansion potential for bireociclib. Actual results may differ due to risks including competitive pricing pressure, reimbursement negotiation timelines, and long\u2011term overall survival data requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030300920_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030300920_c.\"><\/object><a id=\"wp-block-file--media-118e4db2-7132-4985-8218-40af16b21086\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030300920_c.pdf\">2026030300920_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030300920_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-118e4db2-7132-4985-8218-40af16b21086\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\/4\/6 inhibitor developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58773,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,930,15,146],"class_list":["post-58761","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-0460","tag-product-approvals","tag-sihuan-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sihuan Pharma&#039;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\/4\/6 inhibitor developed by subsidiary Xuanzhu Biopharmaceutical, has received NMPA approval for first\u2011line treatment of HR+\/HER2\u2011 advanced breast cancer in combination with an aromatase inhibitor (AI). The approval\u2014based on BRIGHT\u20113 study data showing superior progression\u2011free survival\u2014marks the third indication for the first\u2011in\u2011class multi\u2011target CDK inhibitor in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58761\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sihuan Pharma&#039;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label\" \/>\n<meta property=\"og:description\" content=\"Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\/4\/6 inhibitor developed by subsidiary Xuanzhu Biopharmaceutical, has received NMPA approval for first\u2011line treatment of HR+\/HER2\u2011 advanced breast cancer in combination with an aromatase inhibitor (AI). The approval\u2014based on BRIGHT\u20113 study data showing superior progression\u2011free survival\u2014marks the third indication for the first\u2011in\u2011class multi\u2011target CDK inhibitor in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58761\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T08:42:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T08:42:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sihuan Pharma&#8217;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\\\/HER2\u2011 Breast Cancer \u2013 CDK2\\\/4\\\/6 Inhibitor Expands Label\",\"datePublished\":\"2026-03-04T08:42:58+00:00\",\"dateModified\":\"2026-03-04T08:42:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761\"},\"wordCount\":461,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0407.webp\",\"keywords\":[\"Cancer\",\"HKG: 0460\",\"Product approvals\",\"Sihuan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58761#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58761\",\"name\":\"Sihuan Pharma's Bireociclib Wins NMPA Approval for First\u2011Line HR+\\\/HER2\u2011 Breast Cancer \u2013 CDK2\\\/4\\\/6 Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0407.webp\",\"datePublished\":\"2026-03-04T08:42:58+00:00\",\"dateModified\":\"2026-03-04T08:42:59+00:00\",\"description\":\"Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\\\/4\\\/6 inhibitor developed by subsidiary Xuanzhu Biopharmaceutical, has received NMPA approval for first\u2011line treatment of HR+\\\/HER2\u2011 advanced breast cancer in combination with an aromatase inhibitor (AI). The approval\u2014based on BRIGHT\u20113 study data showing superior progression\u2011free survival\u2014marks the third indication for the first\u2011in\u2011class multi\u2011target CDK inhibitor in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58761\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0407.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0407.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sihuan Pharma's Bireociclib Wins NMPA Approval for First\u2011Line HR+\\\/HER2\u2011 Breast Cancer \u2013 CDK2\\\/4\\\/6 Inhibitor Expands Label\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58761#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sihuan Pharma&#8217;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\\\/HER2\u2011 Breast Cancer \u2013 CDK2\\\/4\\\/6 Inhibitor Expands Label\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sihuan Pharma's Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry","description":"Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\/4\/6 inhibitor developed by subsidiary Xuanzhu Biopharmaceutical, has received NMPA approval for first\u2011line treatment of HR+\/HER2\u2011 advanced breast cancer in combination with an aromatase inhibitor (AI). The approval\u2014based on BRIGHT\u20113 study data showing superior progression\u2011free survival\u2014marks the third indication for the first\u2011in\u2011class multi\u2011target CDK inhibitor in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58761","og_locale":"en_US","og_type":"article","og_title":"Sihuan Pharma's Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label","og_description":"Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\/4\/6 inhibitor developed by subsidiary Xuanzhu Biopharmaceutical, has received NMPA approval for first\u2011line treatment of HR+\/HER2\u2011 advanced breast cancer in combination with an aromatase inhibitor (AI). The approval\u2014based on BRIGHT\u20113 study data showing superior progression\u2011free survival\u2014marks the third indication for the first\u2011in\u2011class multi\u2011target CDK inhibitor in China.","og_url":"https:\/\/flcube.com\/?p=58761","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-04T08:42:58+00:00","article_modified_time":"2026-03-04T08:42:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58761#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58761"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sihuan Pharma&#8217;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label","datePublished":"2026-03-04T08:42:58+00:00","dateModified":"2026-03-04T08:42:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58761"},"wordCount":461,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58761#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp","keywords":["Cancer","HKG: 0460","Product approvals","Sihuan Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58761#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58761","url":"https:\/\/flcube.com\/?p=58761","name":"Sihuan Pharma's Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58761#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58761#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp","datePublished":"2026-03-04T08:42:58+00:00","dateModified":"2026-03-04T08:42:59+00:00","description":"Sihuan Pharmaceutical Holdings Group Ltd (HKG:\u202f0460) announced that Xuanyuening (bireociclib), a Category\u202f1 CDK2\/4\/6 inhibitor developed by subsidiary Xuanzhu Biopharmaceutical, has received NMPA approval for first\u2011line treatment of HR+\/HER2\u2011 advanced breast cancer in combination with an aromatase inhibitor (AI). The approval\u2014based on BRIGHT\u20113 study data showing superior progression\u2011free survival\u2014marks the third indication for the first\u2011in\u2011class multi\u2011target CDK inhibitor in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58761#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58761"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58761#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp","width":1080,"height":608,"caption":"Sihuan Pharma's Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58761#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sihuan Pharma&#8217;s Bireociclib Wins NMPA Approval for First\u2011Line HR+\/HER2\u2011 Breast Cancer \u2013 CDK2\/4\/6 Inhibitor Expands Label"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0407.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58761"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58761\/revisions"}],"predecessor-version":[{"id":58775,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58761\/revisions\/58775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58773"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}